2026-10-08 エディンバラ大学
＜関連情報＞
- https://www.ed.ac.uk/news/stark-differences-in-rsv-vaccine-uptake
- https://www.thelancet.com/journals/lanepe/article/PIIS2666-7762(26)00259-0/fulltext
母親のRSVワクチン接種率、有効性、安全性に関する実世界のエビデンス：系統的レビューとメタ分析 Real-world evidence on maternal RSV vaccination uptake, effectiveness, and safety: a systematic review and meta-analysis
Evelyn Balsells ∙ Sohail Ferdous ∙ Daira Trusinska ∙ Bohee Lee ∙ Louise Lansbury ∙ Cedric Burden ∙ et al.
The Lancet Regional Health – Europe Published: October 7, 2026
DOI:https://doi.org/10.1016/j.lanepe.2026.101847
Summary
Background
Maternal vaccination against respiratory syncytial virus (RSV)- associated lower respiratory tract infections (LRTI) is available to protect infants during their most vulnerable early months. As the vaccine is rolled out globally, it is important to investigate vaccine uptake, effectiveness, and safety outcomes to inform future research and implementation strategies.
Methods
From November 2024 to November 2025, we conducted monthly searches of Ovid databases to identify studies reporting real-world evidence on maternal RSV vaccine uptake, effectiveness, and safety. Studies were screened, relevant data were extracted, and risk-of-bias was assessed by at least two reviewers. Meta-analyses were performed for outcomes with three or more datapoints. Narrative synthesis was performed for other outcomes. PROSPERO registration: CRD42025643585.
Findings
Of 5343 studies identified, 21 were included. We estimated an overall uptake of 27.1% (95% confidence interval (CI): 19.1–37.0; I2: 99.9%; N = 1,308,447 pregnancies in 13 studies) through the seasonal vaccination programme during the 2023/24 RSV season in the United States. The pooled vaccine effectiveness against RSV-associated LRTI hospitalisation in infants younger than six months was 73.6% (95% CI: 66.3–81.0; I2: 0.0%) based on four studies including 2478 infants. Regarding safety, no significant association was identified between vaccination at 32–35 weeks of pregnancy and preterm birth (OR 0.99 (95% CI: 0.87–1.10); I2: 0.0%, N = 16,394 pregnancies in 3 studies).
Interpretation
Maternal RSV vaccination is effective in preventing RSV-associated LRTI hospitalisation during the first six months of life. More data are required to characterise vaccine effectiveness in narrower age groups. Safety findings support a favourable profile in pregnant individuals. Larger studies, particularly from settings where vaccination is available before 32 weeks’ gestation, are required to improve the accuracy for preterm birth estimates, assess other perinatal outcomes, and enhance generalisability. Efforts to increase uptake and reduce disparities will be essential to maximise the benefits of maternal RSV vaccination.
Funding
None.
